SCHEMBL3387151

SCHEMBL3387151

O=C1CCCC(S(=O)(=O)c2ccccc2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
AKR1C3 P42330 3/20 0.46
HTR2A P28223 3/20 0.43
MMP8 P22894 2/20 0.41
MMP13 P45452 2/20 0.41
MMP1 P03956 1/20 0.41
KCNH2 Q12809 2/20 0.41
HTR2C P28335 1/20 0.41
ALDH1A1 P00352 5/20 0.40
GAA P10253 1/20 0.39
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TSHR P16473 1/20 0.37
PARL Q9H300 1/20 0.37
ACHE P22303 1/20 0.37
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7541817 0.79 HTR2A (0.56) MAPTAKR1C3HTR2AMMP8MMP13
SCHEMBL777971 0.79 MAPT (0.56) MAPTAKR1C3HTR2AMMP8MMP13
SCHEMBL776895 0.77 MAPT (0.55) MAPTHTR2AMMP8MMP13MMP1
SCHEMBL10878628 0.76 MAPT (0.46) MAPTAKR1C3HTR2AMMP8MMP13
SCHEMBL10880644 0.76 MAPT (0.43) MAPTAKR1C3HTR2AMMP8MMP13
SCHEMBL2048495 0.75 HTR2A (0.59) MAPTAKR1C3HTR2AMMP8MMP13
SCHEMBL8535231 0.73 MAPT (0.36) MAPTALDH1A1
SCHEMBL9835230 0.72 KDM4E (0.54) MAPTMMP13ALDH1A1GAAPOLB
SCHEMBL24483600 0.71 MAPT (0.49) MAPTAKR1C3HTR2AMMP8MMP13
SCHEMBL24483471 0.71 MAPT (0.49) MAPTAKR1C3HTR2AMMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1839653-B9 THERAPEUTIC AGENT FOR SENSORY DISORDERS MEIJI DAIRIES CORP (JP) 2010-12-22 EP disclosed
EP-2196200-A1 Cyclohexenone derivative for treating or preventing hypesthesia or hyperesthesia caused by diabetes Meiji Dairies Corporation (JP) 2010-06-16 EP disclosed
EP-1839653-B1 THERAPEUTIC AGENT FOR SENSORY DISORDERS MEIJI DAIRIES CORP (JP) 2010-06-09 EP disclosed
US-20090069442-A1 Therapeutic Agent for Sensory Abnormality MEIJI CO., LTD (JP) 2009-03-12 US disclosed
US-20080312336-A1 Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder UNIVERSITE DE STRASBOURG (FR) 2008-12-18 US disclosed
EP-1839653-A1 THERAPEUTIC AGENT FOR SENSORY ABNORMALITY Meiji Dairies Corporation (JP) 2007-10-03 EP disclosed
US-7166642-B1 Use of cyclohexenone long-chain alcohol for treating neurodegenerative diseases MEIJI DAIRIES CORPORATION (JP) 2007-01-23 US disclosed
EP-1150667-B1 CYCLOHEXENONE LONG-CHAIN ALCOHOL FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS MEIJI DAIRIES CORP (JP) 2004-07-14 EP disclosed
EP-1003706-B1 CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME MEIJI MILK PROD CO LTD (JP) 2003-03-05 EP disclosed
EP-1150667-A1 CYCLOHEXENONE LONG-CHAIN ALCOHOL FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS Meiji Dairies Corporation (JP) 2001-11-07 EP disclosed
US-6228893-B1 TREATING DEMENTIA MEIJI MILK PRODUCTS CO., LTD. (JP) 2001-05-08 US disclosed
WO-2000047199-A1 USE OF A CYCLOHEXENONE LONG-CHAIN ALCOHOL FOR TREATING NEURODEGENERATIVE DISEASES MEIJI DAIRIES CORPORATION (JP) 2000-08-17 WO disclosed
EP-1003706-A1 CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME MEIJI MILK PRODUCTS COMPANY LIMITED (JP) 2000-05-31 EP disclosed
WO-1999008987-A1 CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME MEIJI MILK PRODUCTS CO., LTD. (JP) 1999-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312336-A1 Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder CPT1B, CHRM1, ADRA1D MAPT 4599/4885AKR1C3 36/4885HTR2A 3664/4885
US-20090069442-A1 Therapeutic Agent for Sensory Abnormality PMP22, NGF, HRH1 MAPT 3594/4885AKR1C3 62/4885HTR2A 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.